Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Innovative Imaging Technology Overcoming Challenges Involving Bladder Cancer Visualization
90% of the cystoscopies performed on bladder cancer patients use white light, which cannot always detect cancer margins or tumors that lie flat against the bladder wall. The American Urology Association recommends blue light for cystoscopic procedures involving bladder cancer. Imagin Medical’s i/Blue Imaging System(TM) provides the simultaneous, side-by-side display of white light and blue light images, making it easier to visualize cancer margins and flat tumors, potentially resulting in lower recurrence rates The company is has transitioned to the manufacturing stage of the i/Blue System with their contract manufacturer, Lighthouse Imaging Bladder cancer is the sixth most prevalent cancer…